Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.9700
+0.0201 (2.12%)
At close: Apr 25, 2025, 4:00 PM
0.9690
-0.0010 (-0.10%)
After-hours: Apr 25, 2025, 6:40 PM EDT
Scienture Holdings Revenue
In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -89.98%. Scienture Holdings had revenue of $53.08K in the quarter ending December 31, 2024, a decrease of -58.74%.
Revenue (ttm)
$136.64K
Revenue Growth
-89.98%
P/S Ratio
24.46
Revenue / Employee
$7,192
Employees
19
Market Cap
12.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
| Dec 31, 2022 | 300.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 5 days ago - SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - GlobeNewsWire
- 19 days ago - SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - GlobeNewsWire
- 24 days ago - Scienture Holdings, Inc. Issues Annual Letter to Shareholders - GlobeNewsWire
- 4 weeks ago - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - GlobeNewsWire
- 5 weeks ago - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - GlobeNewsWire
- 5 weeks ago - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - GlobeNewsWire
- 7 weeks ago - SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. - GlobeNewsWire
- 3 months ago - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics - GlobeNewsWire